169 related articles for article (PubMed ID: 24477603)
1. An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors.
Murakami H; Kurata T; Onozawa Y; Watanabe J; Ono A; Takahashi T; Yamamoto N; Fujisaka Y; Kiyota H; Hayashi H; Tanaka K; Nakagawa K; Kuroda S
Cancer Chemother Pharmacol; 2014 Mar; 73(3):623-30. PubMed ID: 24477603
[TBL] [Abstract][Full Text] [Related]
2. Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
Sessa C; Lorusso P; Tolcher A; Farace F; Lassau N; Delmonte A; Braghetti A; Bahleda R; Cohen P; Hospitel M; Veyrat-Follet C; Soria JC
Clin Cancer Res; 2013 Sep; 19(17):4832-42. PubMed ID: 23833302
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors.
Matsumoto K; Sunaga Y; Ecstein-Fraisse E; Fujiwara K
Int J Gynecol Cancer; 2024 Apr; 34(4):586-593. PubMed ID: 37989482
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
Bahleda R; Sessa C; Del Conte G; Gianni L; Capri G; Varga A; Oprea C; Daglish B; Hospitel M; Soria JC
Invest New Drugs; 2014 Dec; 32(6):1188-96. PubMed ID: 24898305
[TBL] [Abstract][Full Text] [Related]
5. A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.
Eskens FA; Tresca P; Tosi D; Van Doorn L; Fontaine H; Van der Gaast A; Veyrat-Follet C; Oprea C; Hospitel M; Dieras V
Br J Cancer; 2014 Apr; 110(9):2170-7. PubMed ID: 24714750
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors.
Takahashi S; Nakano K; Yokota T; Shitara K; Muro K; Sunaga Y; Ecstein-Fraisse E; Ura T
Jpn J Clin Oncol; 2016 Nov; 46(11):1000-1007. PubMed ID: 27566973
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of ombrabulin in combination with docetaxel and cisplatin in Japanese patients with advanced solid tumors.
Nishio M; Satouchi M; Horiike A; Horio Y; Sunaga Y; Ecstein-Fraisse E; Hida T
Jpn J Clin Oncol; 2018 Apr; 48(4):322-328. PubMed ID: 29514256
[TBL] [Abstract][Full Text] [Related]
8. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
9. First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors.
Baird RD; Linossi C; Middleton M; Lord S; Harris A; Rodón J; Zitt C; Fiedler U; Dawson KM; Leupin N; Stumpp MT; Harstrick A; Azaro A; Fischer S; Omlin A
J Clin Oncol; 2021 Jan; 39(2):145-154. PubMed ID: 33301375
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors.
Nokihara H; Yamada Y; Fujiwara Y; Yamamoto N; Wakui H; Nakamichi S; Kitazono S; Inoue K; Harada A; Taube T; Takeuchi Y; Tamura T
Invest New Drugs; 2016 Feb; 34(1):66-74. PubMed ID: 26627079
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors.
Doi T; Onozawa Y; Fuse N; Yoshino T; Yamazaki K; Watanabe J; Akimov M; Robson M; Boku N; Ohtsu A
Cancer Chemother Pharmacol; 2014 Sep; 74(3):629-36. PubMed ID: 25059319
[TBL] [Abstract][Full Text] [Related]
12. Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
Blay JY; Pápai Z; Tolcher AW; Italiano A; Cupissol D; López-Pousa A; Chawla SP; Bompas E; Babovic N; Penel N; Isambert N; Staddon AP; Saâda-Bouzid E; Santoro A; Franke FA; Cohen P; Le-Guennec S; Demetri GD
Lancet Oncol; 2015 May; 16(5):531-40. PubMed ID: 25864104
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
14. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
Doi T; Ohtsu A; Tahara M; Tamura T; Shirao K; Yamada Y; Otani S; Yang BB; Ohkura M; Ohtsu T
Int J Clin Oncol; 2009 Aug; 14(4):307-14. PubMed ID: 19705240
[TBL] [Abstract][Full Text] [Related]
16. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.
Reid T; Oronsky B; Scicinski J; Scribner CL; Knox SJ; Ning S; Peehl DM; Korn R; Stirn M; Carter CA; Oronsky A; Taylor MJ; Fitch WL; Cabrales P; Kim MM; Burris HA; Lao CD; Abrouk NED; Fanger GR; Infante JR
Lancet Oncol; 2015 Sep; 16(9):1133-1142. PubMed ID: 26296952
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors.
Tamura Y; Nokihara H; Honda K; Tanabe Y; Asahina H; Yamada Y; Enatsu S; Kurek R; Yamamoto N; Tamura T
Cancer Chemother Pharmacol; 2016 Nov; 78(5):995-1002. PubMed ID: 27628194
[TBL] [Abstract][Full Text] [Related]
20. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
